CancerVax, Inc., the developer of a breakthrough universal cancer treatment (UCT) platform that will use the body’s immune system to fight cancer, today announced the successful functional validation of its innovative Smart mRNA (messenger RNA) technology in lab tests
CancerVax, Inc., the developer of a breakthrough universal cancer treatment (UCT) platform that will use the body’s immune system to fight cancer, announced today that the Company has selected Pancreatic Ductal Adenocarcinoma (PDAC) as one of its first targets for preclinical development
CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform that will use the body’s immune system to fight cancer, announced today that Dr. George Katibah will serve as the company’s Chief Scientific Officer
Cancervax, Inc., the developer of a breakthrough universal cancer treatment platform that will use the body’s immune system to fight cancer, today announced that the Company has entered into a research agreement with Flashpoint Therapeutics to perform research on its newly patent-pending Universal Cancer Treatment platform
Cancervax, Inc., the developer of a breakthrough universal cancer treatment platform that will use the body’s immune system to fight cancer, today announced that the Company has recently filed a new patent application which includes a Smart mRNA Technology. mRNA, short for messenger RNA, is the underlying technology that made the COVID-19 vaccine so effective and inexpensive
Cancervax, Inc., the developer of breakthrough cancer drugs that will use the body’s immune system to fight cancer, today announced that the Company has added two key members to its cancer research team. Dr. Jonathan Lakey will serve as Chief Scientific Advisor and Dr. Adam Grant will serve as Principal Scientist
Cancervax, Inc., the developer of breakthrough cancer drugs that will use the body’s immune system to fight cancer, today announced that its UCLA research team has achieved a critical milestone by creating a process to add any antibody to lipid nanoparticles (LNP) using “click chemistry”, for targeting cancer cells
Cancervax, Inc., the developer of breakthrough cancer drugs that will use the body’s immune system to fight cancer, today announced that its UCLA research team has created a promising new drug candidate for treating recurrent Ewing sarcoma, a deadly children’s cancer
Cancervax, Inc., developer of a breakthrough Universal Cancer Treatment that will use the body’s immune system to fight cancer, today announced that its Reg A+ offering has been qualified by the SEC allowing the Company to formally launch a funding round of up to $5 million. Proceeds from the SEC qualified Reg A+ offering will be used by the Company to continue work on its breakthrough cancer treatments
Cancervax, Inc., developer of a breakthrough universal cancer treatment that uses the body’s immune system to fight cancer, today announced that in a recent Company podcast its CEO, Ryan Davies, and Tempus Labs Chief Medical Officer for Oncology Dr. Ezra Cohen, discussed his time at Tempus Labs, Moores Cancer Center and University of Chicago
Cancervax, Inc., a pre-clinical biotechnology company working with UCLA to develop breakthrough immunotherapy cancer treatments that use the body’s immune system to fight cancer, today announced an expansion of its development pipeline to include a Universal CAR-T Cell Platform that can dramatically lower the cost of CAR-T cell cancer therapies
Cancervax, Inc., developer of a breakthrough universal cancer treatment that uses the body’s immune system to fight cancer, today announced that in a recent Company podcast its CEO, Ryan Davies, spoke with and UCLA cancer physician and researcher, Dr. Steven Jonas, about his journey to becoming both a practicing cancer doctor and active cancer researcher
Three separate teams of physician scientists at UCLA working on three different parts of the project have made significant progress and are ready to merge their work into a complete proof-of-concept vaccine construct
Lehi, UT – May 17, 2023 – Cancervax, developer of a breakthrough universal cancer treatment that will use the body’s immune system to fight cancer, today reported that the Company’s CEO, Ryan Davies
Dr. Ryan Looper, a chemistry Professor at the University of Utah, sat down with Cancervax CEO Ryan Davies to discuss the future of novel therapeutics and how the industry can encourage young scientists to enter the field.
Dr. Jonathan Lakey, Professor in University of California – Irvine’s Surgery and Biomedical Engineering departments, spoke with Cancervax CEO Ryan Davies on his accomplishments in scientific research and their impact on the world
The UCLA research team, which includes Dr. Steven Jonas, Dr. Christopher Seet, Dr. Satiro De Oliveira and Dr. Christopher Denny, will leverage cutting-edge technologies to develop a breakthrough universal cancer treatment that will train the body to target and destroy cancer cells.